Shingrix Could Protect the Heart for Years, Study Suggests

A US study of about 70,000 adults aged 60+ found that the recombinant shingles vaccine Shingrix is associated with a lower risk of cardiovascular disease years after vaccination compared with the older live vaccine, with the strongest effect on ischemic heart disease and heart failure; the finding hints at immune-system changes beyond shingles, though the observational design aims to reduce bias by comparing groups who chose vaccination rather than vaccinated versus unvaccinated.